Welcome to SWEBAGS
The Swedish Basal Ganglia Society, SWEBAGS, is an non-profit scientific organization providing a platform for discussions and education opportunities in the area of basal ganglia research.
We aim to increase the visibility of mainly basic and pre-clinical research, and foster multidisciplinary collaborations across biological scales and methodological approaches. All professionals, students and organisations interested in basal ganglia research are welcome to become members.
Together we will leverage the strengths of basal ganglia research in Sweden, join us in our efforts and participate in our activities!
– Jeanette Hellgren Kotaleski, Professor, KTH Royal Institute of technology, Chair SWEBAGS
– Angela Cenci Nilsson, Professor, Lund University, Vice Chair SWEBAGS
Latest News:
New Publication: Concerning neuromodulation as treatment of neurological and neuropsychiatric disorder: Insights gained from selective targeting of the subthalamic nucleus, para-subthalamic nucleus and zona incerta in rodents
Authors: Alessia Ricci, Eleonora Rubino, Gian Pietro Serra, Åsa Wallén-Mackenzie Abstract: Neuromodulation such as deep brain stimulation (DBS) is advancing as a clinical intervention in several neurological and neuropsychiatric disorders, including Parkinson´s disease, dystonia, tremor, and obsessive-compulsive disorder (OCD) for which DBS is already applied to alleviate severely afflicted individuals of symptoms. Tourette syndrome and…
SWEBAGS Conference 2024
SWEBAGS warmly welcomes you to the SWEBAGS Conference 2024. Based on the previous year’s successes, we will try to incorporate the feedback from the previous years when we once more open our digital doors for an online one-day conference on December 5th 2024. One thing that many have requested has been to minimize the systems…
New Publication: Neurophysiological treatment effects of mesdopetam, pimavanserin and clozapine in a rodent model of Parkinson’s disease psychosis
Authors: Tiberiu Loredan Stan, Abdolaziz Ronaghi, Sebastian A. Barrientos, Pär Halje, Luciano Censoni, Emilio Garro-Martínez, Azat Nasretdinov, Evgenya Malinina, Stephan Hjorth, Peder Svensson, Susanna Waters, Kristoffer Sahlholm, Per Petersson Abstract: Psychosis in Parkinson’s disease is a common phenomenon associated with poor outcomes. To clarify the pathophysiology of this condition and the mechanisms of antipsychotic treatments, we have here characterized the neurophysiological brain states induced by clozapine, pimavanserin, and the novel prospective antipsychotic mesdopetam in a rodent model of Parkinson’s disease…
